JP2019523633A5 - - Google Patents

Download PDF

Info

Publication number
JP2019523633A5
JP2019523633A5 JP2018556357A JP2018556357A JP2019523633A5 JP 2019523633 A5 JP2019523633 A5 JP 2019523633A5 JP 2018556357 A JP2018556357 A JP 2018556357A JP 2018556357 A JP2018556357 A JP 2018556357A JP 2019523633 A5 JP2019523633 A5 JP 2019523633A5
Authority
JP
Japan
Prior art keywords
cancer
disease
syndrome
inflammation
isolated peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018556357A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019523633A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/030100 external-priority patent/WO2017189988A1/en
Publication of JP2019523633A publication Critical patent/JP2019523633A/ja
Publication of JP2019523633A5 publication Critical patent/JP2019523633A5/ja
Pending legal-status Critical Current

Links

JP2018556357A 2016-04-29 2017-04-28 組織の損傷に関連した疾患及び障害を予防及び治療する組織保護ペプチド Pending JP2019523633A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662329743P 2016-04-29 2016-04-29
US62/329,743 2016-04-29
PCT/US2017/030100 WO2017189988A1 (en) 2016-04-29 2017-04-28 Tissue protective peptides for preventing and treating diseases and disorders associated with tissue damage

Publications (2)

Publication Number Publication Date
JP2019523633A JP2019523633A (ja) 2019-08-29
JP2019523633A5 true JP2019523633A5 (https=) 2020-06-18

Family

ID=60161215

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018556357A Pending JP2019523633A (ja) 2016-04-29 2017-04-28 組織の損傷に関連した疾患及び障害を予防及び治療する組織保護ペプチド

Country Status (5)

Country Link
US (1) US10864253B2 (https=)
EP (1) EP3448415A4 (https=)
JP (1) JP2019523633A (https=)
CN (1) CN109310741A (https=)
WO (1) WO2017189988A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020245535B2 (en) * 2019-03-26 2022-06-30 Pinova Therapeutics Inc. Devices and methods for delivering pharmaceutical compositions
US12377112B2 (en) * 2019-04-17 2025-08-05 Compass Pathfinder Limited Methods of treating neurocognitive disorders, chronic pain and reducing inflammation
BR112022009955A2 (pt) * 2019-12-13 2022-08-09 Massachusetts Inst Technology Barreiras de tecido sintético e seus usos
EP4276105A4 (en) * 2021-01-11 2024-12-18 Sichuan Gooddoctor Panxi Pharmaceutical Co. Ltd POLYPEPTIDE FOR REPAIRING A SKIN WOUND OR A MUCOSAL INJURY, AND ITS USE
CN119908970B (zh) * 2025-01-23 2026-02-03 诺德溯源(广州)生物科技有限公司 一种用于改善女性更年期衰老的护肤组合物及其应用

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1479268A (en) 1973-07-05 1977-07-13 Beecham Group Ltd Pharmaceutical compositions
CH596313A5 (https=) 1975-05-30 1978-03-15 Battelle Memorial Institute
US4414147A (en) 1981-04-17 1983-11-08 Massachusetts Institute Of Technology Methods of decreasing the hydrophobicity of fibroblast and other interferons
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US5051448A (en) 1984-07-24 1991-09-24 The Mclean Hospital Corporation GABA esters and GABA analog esters
JP2524586B2 (ja) 1985-06-26 1996-08-14 シタス コーポレイション ポリマ−接合を利用する医薬組成物用蛋白質の可溶化
US5192746A (en) 1990-07-09 1993-03-09 Tanabe Seiyaku Co., Ltd. Cyclic cell adhesion modulation compounds
WO1994005332A2 (en) 1992-09-01 1994-03-17 Berlex Laboratories, Inc. Glycolation of glycosylated macromolecules
US5559103A (en) 1993-07-21 1996-09-24 Cytel Corporation Bivalent sialyl X saccharides
US5576423A (en) 1994-12-02 1996-11-19 Schering Corporation Antibodies to the slam protein expressed on activated T cells
IL114407A0 (en) * 1995-06-30 1995-10-31 Yeda Res & Dev Novel peptides and pharmaceutical compositions comprising them
IL114458A0 (en) * 1995-07-05 1995-11-27 Yeda Res & Dev Therapeutic preparations for treatment of T cell mediated diseases
US20030072737A1 (en) 2000-12-29 2003-04-17 Michael Brines Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs
US7767643B2 (en) 2000-12-29 2010-08-03 The Kenneth S. Warren Institute, Inc. Protection, restoration, and enhancement of erythropoietin-responsive cells, tissues and organs
PA8536201A1 (es) 2000-12-29 2002-08-29 Kenneth S Warren Inst Inc Protección y mejoramiento de células, tejidos y órganos que responden a la eritropoyetina
AU2003228099A1 (en) * 2002-07-03 2004-01-23 Centro Cardiologico Monzino S.P.A.-Irccs Use of hmgb1 in the treatment of tissue damage and/or to promote tissue repair
WO2004022577A2 (en) 2002-09-09 2004-03-18 Warren Pharmaceuticals, Inc. Long acting erythropoietins that maintain tissue protective activity of endogenous erythropoietin
WO2005025606A1 (en) 2003-09-09 2005-03-24 Warren Pharmaceuticals, Inc. Long acting erythropoietins that maintain tissue protective activity of endogenous erythropoietin
WO2005032467A2 (en) 2003-09-29 2005-04-14 Warren Pharmaceuticals, Inc. Tissue protective cytokines for the treatment and prevention of sepsis and the formation of adhesions
WO2005048914A2 (en) * 2003-11-24 2005-06-02 Yeda Research & Development Co. Ltd. Dna vaccines encoding hsp60 peptide fragments for treating autoimmune diseases
AU2005207891B2 (en) * 2004-01-28 2010-04-01 Andromeda Biotech Ltd. Hsp therapy in conjunction with a low antigenicity diet
US20080305120A1 (en) 2004-06-17 2008-12-11 Medimmune, Inc. Immunogenic Compositions Comprising Hmgb 1 Polypeptides
CN101151043B (zh) * 2004-12-21 2013-09-04 南卡罗来纳州医科大学研究发展基金会 促进伤口愈合和组织再生的组合物和方法
EP2374474A1 (en) * 2005-01-19 2011-10-12 Vaxinnate Corporation Compositions comprising pathogen-associated molecular patterns and antigens and their use to stimulate an immune response
SI2540309T1 (en) 2005-08-05 2018-04-30 Araim Pharmaceuticals, Inc. Tissue protective peptides and their uses
CU23632A1 (es) * 2006-04-28 2011-02-24 Ct Ingenieria Genetica Biotech Métodos para la identificación de candidatos terapéuticos contra enfermedades causadas por flavivirus y moléculas antivirales.
KR20200075044A (ko) 2008-01-22 2020-06-25 아라임 파마슈티칼즈, 인크. 조직 손상 관련 질환 및 장애를 예방 및 치료하기 위한 조직 보호 펩티드 및 펩티드 유사체
PT3358011T (pt) 2011-04-26 2020-04-23 Univ Osaka Péptido para induzir a regeneração de um tecido e a sua utilização
WO2012170742A2 (en) 2011-06-07 2012-12-13 University Of Hawaii Treatment and prevention of cancer with hmgb1 antagonists
US9046530B2 (en) * 2011-12-02 2015-06-02 Board Of Regents, The University Of Texas System Methods and compositions for chlamydial antigens as reagents for diagnosis of tubal factor infertility and chlamydial infection
CA2918223A1 (en) 2013-07-17 2015-01-22 Araim Pharmaceuticals, Inc. Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage
US9840555B2 (en) * 2013-11-04 2017-12-12 Li-Te Chin Method for producing human monoclonal antibodies that binds to at least one part of HMGB1
CU20140026A7 (es) * 2014-03-03 2015-11-27 Ct De Ingeniería Genética Y Biotecnología Biocubafarma Péptidos horquilla beta con propiedades antivirales contra el virus dengue

Similar Documents

Publication Publication Date Title
JP2019523633A5 (https=)
JP2016531105A5 (https=)
AU2020281003B2 (en) Process for preparing an anti-cancer agent, 1-((4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-6-methoxyquinolin-7-yloxy)methyl) cyclopropanamine, its crystalline form and its salts
ES2901711T3 (es) Ciclopropilaminas como inhibidores de LSD1
TWI242559B (en) Chemical compounds
AU2024227527A1 (en) Modulators of the integrated stress pathway
ES2718409T3 (es) Síntesis de compuestos de carbomoilpiridona policíclica
ES2690082T3 (es) Derivados de purina para el tratamiento de infecciones virales
JP2021524838A5 (https=)
ES2709975T3 (es) Compuestos inmunomoduladores y antiinflamatorios novedosos
BR112020006780A2 (pt) moduladores do estimulador de genes do interferon (sting)
ES2499028T3 (es) Derivados de anilino-pirimidina sustituidos con sulfoximina como inhibidores de CDK, su preparación y uso como medicamentos
ES2805835T3 (es) Compuestos policíclicos como inhibidores de quinasa de tirosina de Bruton
SG194852A1 (en) Quinazoline derivatives for the treatment of viral infections and further diseases
KR20180124149A (ko) 단백질 조정제로서 유용한 헤테로시클릭 아미드
RU2014121073A (ru) Бициклические соединения пиперазина
AU2013326429B2 (en) N-prop-2-ynyl carboxamide derivatives and their use as TRPA1 antagonists
SA515360611B1 (ar) مشتقات كلورو-بيرازين كربوكساميد مفيدة لعلاج أمراض مصحوبة بترطيب مخاطي غير كافي
US10987349B2 (en) Antitumor agent and bromodomain inhibitor
WO2009067856A1 (fr) Inhibiteur de l'histone désacétylase, composition et utilisation de celui-ci
WO2019100061A1 (en) Oxoacridinyl acetic acid derivatives and methods of use
CN107735401A (zh) 取代二氢吡咯并吡唑衍生物
JP6262363B2 (ja) ブロモドメイン阻害剤としてのキノリン誘導体
ES2963447T3 (es) Nuevos procesos e intermediarios para la preparación de estimulantes de guanilato ciclasa soluble
PE20260309A1 (es) Formas de sal y cristalinas de un compuesto organico y composiciones farmaceuticas del mismo